Qualitative Development and Cognitive Evaluation of the Symptoms of Major Depressive Disorder (S-MDD), A Consortium-Developed Patient Reported Outcome Measure
C-Path’s PSTC Releases Points to Consider Outlining Recommendations for Analytical Validation of Assays Used in Qualifying Biomarkers The document serves as a guide to the analysis of biomarkers in drug development TUCSON, Ariz., June 11, 2019 — The Critical Pat
C-Path Receives Qualification for the Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) TUCSON, Ariz., April 9, 2019 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces U.S.
C-Path Appoints Dr. Amanda Klein as Executive Director for CPLD and CPA-1 Consortia TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as E
C-Path Forms Data Collaboration with International Niemann-Pick Disease Registry (INPDR) to Propel Niemann-Pick Disease Research Forward TUCSON, Ariz. April 17, 2024 — Critical Path Institute (C-Path), a leader in advancing rare disease research, today announced a
C-Path Inaugural Global Impact Conference: Pioneering Drug Development Collaborations Sept. 9-11, 2024, Washington, D.C. TUCSON, Ariz., August 7, 2024 – Critical Path Institute (C-Path), whose mission is to lead co
